{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T02:09:49Z","timestamp":1791684589286,"version":"4.3.4"},"reference-count":97,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1016\/j.autrev.2011.06.007","type":"journal-article","created":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T14:27:24Z","timestamp":1309530444000},"page":"6-13","source":"Crossref","is-referenced-by-count":80,"title":["Therapy of polymyositis and dermatomyositis"],"prefix":"10.1016","volume":"11","author":[{"given":"Isabelle","family":"Marie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc","family":"Mouthon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2011.06.007_bb0005","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.revmed.2005.02.002","article-title":"Les nouveaux crit\u00e8res diagnostiques et d'\u00e9valuation des polymyosites et dermatomyosites","volume":"26","author":"Ch\u00e9rin","year":"2005","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.autrev.2011.06.007_bb0010","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/art.21083","article-title":"Opportunistic infections in polymyositis and dermatomyositis","volume":"53","author":"Marie","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2011.06.007_bb0015","unstructured":"Marie, I., Hatron, P.Y., Dominique, S., Ch\u00e9rin, P., Mouthon, L., Menard, J.F. Short term and long term outcome of interstitial lung disease in polymyositis and dermatomyositis: a series of 107 patients. Arthritis Rheum, in press, doi:10\/1002\/art.3015."},{"key":"10.1016\/j.autrev.2011.06.007_bb0020","first-page":"2230","article-title":"Polymyositis and dermatomyositis: short term and longterm outcome, and predictive factors","volume":"28","author":"Marie","year":"2001","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2011.06.007_bb0025","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/00005792-199905000-00001","article-title":"Influence of age on characteristics of polymyositis and dermatomyositis in adults","volume":"78","author":"Marie","year":"1999","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.autrev.2011.06.007_bb0030","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/j.1365-2133.2009.09484.x","article-title":"Long-term outcome of patients with polymyositis\/dermatomyositis and anti-PM-Scl antibody","volume":"162","author":"Marie","year":"2010","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2011.06.007_bb0035","doi-asserted-by":"crossref","first-page":"A330","DOI":"10.1016\/j.autrev.2009.11.006","article-title":"The geoepidemiology of autoimmune muscle disease","volume":"9","author":"Prieto","year":"2010","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2011.06.007_bb0040","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.autrev.2009.12.005","article-title":"Polymyositis, dermatomyositis and malignancy: a further intriguing link","volume":"9","author":"Zampieri","year":"2010","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2011.06.007_bb0045","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1056\/NEJM197502132920706","article-title":"Polymyositis and dermatomyositis","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2011.06.007_bb0050","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJM197502202920807","article-title":"Polymyositis and dermatomyositis","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2011.06.007_bb0055","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1172\/JCI118749","article-title":"Differential expression of perforin in muscle-infiltrating T cells in polymyositis and dermatomyositis","volume":"97","author":"Goebels","year":"1996","journal-title":"J Clin Invest"},{"key":"10.1016\/j.autrev.2011.06.007_bb0060","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/nrrheum.2010.2","article-title":"Immunotherapy of myositis: issues, concerns and future prospects","volume":"6","author":"Dalakas","year":"2010","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2011.06.007_bb0065","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1001\/archderm.1940.01490120003001","article-title":"Dermatomyositis: a study of 40 cases","volume":"41","author":"O'Leary","year":"1940","journal-title":"Arch Dermatol Syphil"},{"key":"10.1016\/j.autrev.2011.06.007_bb0070","first-page":"CD003643","article-title":"Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis","volume":"3","author":"Choy","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.autrev.2011.06.007_bb0075","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jaad.2008.02.043","article-title":"The treatment and prognosis of dermatomyositis: an updated review","volume":"59","author":"Iorizzo","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.autrev.2011.06.007_bb0080","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/0301-0082(90)90026-D","article-title":"Polymyositis and dermatomyositis 1990\u2013diagnosis, treatment and prognosis","volume":"35","author":"Henriksson","year":"1990","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.autrev.2011.06.007_bb0085","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/0002-9343(93)90148-I","article-title":"Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy","volume":"94","author":"Joffe","year":"1993","journal-title":"Am J Med"},{"key":"10.1016\/j.autrev.2011.06.007_bb0090","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/S0190-9622(96)90037-7","article-title":"Guidelines of care for dermatomyositis. American Academy of Dermatology","volume":"34","author":"Drake","year":"1996","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.autrev.2011.06.007_bb0095","first-page":"807","article-title":"Relationship between serum creatine kinase level and corticosteroid therapy in polymyositis-dermatomyositis","volume":"15","author":"Oddis","year":"1988","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2011.06.007_bb0100","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1136\/jnnp.57.8.1008","article-title":"Pulsed intravenous methylprednisolone combined with oral steroids as the initial treatment of inflammatory myopathies","volume":"57","author":"Matsubara","year":"1994","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.autrev.2011.06.007_bb0105","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/art.1780240107","article-title":"Prednisone and azathioprine for polymyositis: long-term follow up","volume":"24","author":"Bunch","year":"1981","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2011.06.007_bb0110","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1177\/088307389801300303","article-title":"Drug therapy in juvenile dermatomyositis: follow-up study","volume":"13","author":"Ng","year":"1998","journal-title":"J Child Neurol"},{"key":"10.1016\/j.autrev.2011.06.007_bb0115","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/0049-0172(90)90024-A","article-title":"Adult-onset polymyositis-dermatomyositis: description of 25 patients with emphasis on treatment","volume":"2","author":"Ram\u00edrez","year":"1990","journal-title":"Semin Arthritis Rheum"},{"issue":"suppl 1","key":"10.1016\/j.autrev.2011.06.007_bb0120","first-page":"S53","article-title":"Randomised double blind controlled trial of methotrexate and steroids compared with azathioprine and steroids in the treatment of idiopathic inflammatory myopathy","volume":"199","author":"Miller","year":"2002","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.autrev.2011.06.007_bb0125","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/ard.41.6.557","article-title":"Intensive immunosuppression versus prednisolone in the treatment of connective tissue diseases","volume":"41","author":"Hollingworth","year":"1982","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2011.06.007_bb0130","doi-asserted-by":"crossref","first-page":"365","DOI":"10.7326\/0003-4819-92-3-365","article-title":"Azathioprine with prednisone for polymyositis. A controlled, clinical trial","volume":"92","author":"Bunch","year":"1980","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.autrev.2011.06.007_bb0135","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/00005792-197707000-00001","article-title":"Computer-assisted analysis of 153 patients with polymyositis and dermatomyositis","volume":"56","author":"Bohan","year":"1977","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.autrev.2011.06.007_bb0140","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1136\/ard.32.6.536","article-title":"Methotrexate therapy in polymyositis","volume":"32","author":"Arnett","year":"1973","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2011.06.007_bb0145","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0190-9622(97)70327-X","article-title":"Low-dose methotrexate administered weekly is an effective corticosteroid-sparing agent for the treatment of the cutaneous manifestations of dermatomyositis","volume":"36","author":"Kasteler","year":"1997","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.autrev.2011.06.007_bb0150","doi-asserted-by":"crossref","first-page":"182","DOI":"10.7326\/0003-4819-81-2-182","article-title":"Polymyositis and dermatomyositis: combined methotrexate and corticosteroid therapy","volume":"81","author":"Metzger","year":"1974","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.autrev.2011.06.007_bb0155","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1002\/art.1780351006","article-title":"Methotrexate treatment of recalcitrant childhood dermatomyositis","volume":"35","author":"Miller","year":"1992","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2011.06.007_bb0160","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/S0140-6736(71)80005-3","article-title":"Treatment of corticosteroid-resistant polymyositis with methotrexate","volume":"1","author":"Sokoloff","year":"1971","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2011.06.007_bb0165","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1002\/1529-0131(199803)41:3<392::AID-ART3>3.0.CO;2-X","article-title":"Treatment of refractory myositis: a randomized crossover study of two new cytotoxic regimens","volume":"41","author":"Villalba","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2011.06.007_bb0170","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/S0190-9622(98)70562-6","article-title":"The value of methotrexate in dermatomyositis","volume":"38","author":"Zieglschmid-Adams","year":"1998","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.autrev.2011.06.007_bb0175","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1196\/annals.1423.052","article-title":"Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspective","volume":"1110","author":"Sib\u00e9ril","year":"2007","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.autrev.2011.06.007_bb0180","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/j.1468-1331.2008.02246.x","article-title":"EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases","volume":"15","author":"Elovaara","year":"2008","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.autrev.2011.06.007_bb0185","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/0091-6749(89)90199-1","article-title":"The use of intravenous immune globulin in collagen vascular disorders: a potentially new modality of therapy","volume":"84","author":"Gelfand","year":"1989","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.autrev.2011.06.007_bb0190","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/0002-9343(91)90009-M","article-title":"Efficacy of intravenous gammaglobulin therapy in chronic refractory polymyositis and dermatomyositis: an open study with 20 adult patients","volume":"91","author":"Cherin","year":"1991","journal-title":"Am J Med"},{"key":"10.1016\/j.autrev.2011.06.007_bb0195","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/0002-9343(91)90010-U","article-title":"Treatment of dermatomyositis with intravenous gammaglobulin","volume":"91","author":"Lang","year":"1991","journal-title":"Am J Med"},{"key":"10.1016\/j.autrev.2011.06.007_bb0200","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJM199312303292704","article-title":"A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis","volume":"329","author":"Dalakas","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2011.06.007_bb0205","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1002\/acr.20325","article-title":"Intravenous immunoglobulins for steroid-refractory esophageal involvement related to polymyositis and dermatomyositis. A series of 73 patients","volume":"62","author":"Marie","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.autrev.2011.06.007_bb0210","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.autrev.2010.09.004","article-title":"Subcutaneous immunoglobulin in polymyositis and dermatomyositis: a novel application","volume":"10","author":"Danieli","year":"2011","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2011.06.007_bb0215","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1136\/jnnp.54.11.1007","article-title":"Cyclosporin in the management of polymyositis and dermatomyositis","volume":"54","author":"Lueck","year":"1991","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.autrev.2011.06.007_bb0220","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1093\/rheumatology\/32.5.439","article-title":"Cyclosporin A in adult dermatomyositis","volume":"32","author":"Keen","year":"1993","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.autrev.2011.06.007_bb0225","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S0140-6736(84)90391-X","article-title":"Cyclosporin for acute dermatomyositis","volume":"1","author":"Zabel","year":"1984","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2011.06.007_bb0230","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1080\/030097400750001897","article-title":"Cyclosporine A versus methotrexate in the treatment of polymyositis and dermatomyositis","volume":"29","author":"Vencovsk\u00fd","year":"2000","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.autrev.2011.06.007_bb0235","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1093\/rheumatology\/keg040","article-title":"Interstitial lung disease associated with juvenile dermatomyositis: clinical features and efficacy of cyclosporin A","volume":"42","author":"Kobayashi","year":"2003","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2011.06.007_bb0240","first-page":"128","article-title":"Usefulness of cyclosporine A on rapidly progressive interstitial pneumonia in dermatomyositis","volume":"19","author":"Miyake","year":"2002","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"10.1016\/j.autrev.2011.06.007_bb0245","first-page":"1527","article-title":"Corticosteroid resistant interstitial pneumonitis in dermatomyositis\/polymyositis: prediction and treatment with cyclosporine","volume":"26","author":"Nawata","year":"1999","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2011.06.007_bb0250","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1080\/08916930500124023","article-title":"Polymyositis\/dermatomyositis and interstitial lung disease: a new therapeutic approach with T-cell-specific immunosuppressants","volume":"38","author":"Takada","year":"2005","journal-title":"Autoimmunity"},{"key":"10.1016\/j.autrev.2011.06.007_bb0255","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/S0140-6736(89)92416-1","article-title":"Cyclophosphamide in severe polymyositis","volume":"1","author":"Bombardieri","year":"1989","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2011.06.007_bb0260","first-page":"1225","article-title":"The failure of intravenous cyclophosphamide therapy in refractory idiopathic inflammatory myopathy","volume":"16","author":"Cronin","year":"1989","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2011.06.007_bb0265","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/rheumatology\/kel112","article-title":"Intravenous cyclophosphamide therapy for progressive interstitial pneumonia in patients with polymyositis\/dermatomyositis","volume":"46","author":"Yamasaki","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2011.06.007_bb0270","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1053\/sarh.2002.50012","article-title":"Interstitial lung disease in polymyositis and dermatomyositis: clinical course and response to treatment","volume":"32","author":"Schnabel","year":"2003","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2011.06.007_bb0275","doi-asserted-by":"crossref","first-page":"428","DOI":"10.2169\/internalmedicine.39.428","article-title":"Successful combined therapy of cyclophosphamide and cyclosporine for acute exacerbated interstitial pneumonia associated with dermatomyositis","volume":"39","author":"Tanaka","year":"2000","journal-title":"Intern Med"},{"key":"10.1016\/j.autrev.2011.06.007_bb0280","first-page":"1719","article-title":"Combination therapy with corticosteroids, cyclosporin A, and intravenous pulse cyclophosphamide for acute\/subacute interstitial pneumonia in patients with dermatomyositis","volume":"32","author":"Kameda","year":"2005","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2011.06.007_bb0285","first-page":"41","article-title":"Clinical experience with mycophenolate mofetil in systemic autoimmune conditions refractory to common immunosuppressive therapies","volume":"139","author":"Bandelier","year":"2009","journal-title":"Swiss Med Wkly"},{"key":"10.1016\/j.autrev.2011.06.007_bb0290","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/archderm.142.1.65","article-title":"Mycophenolate mofetil as an effective corticosteroid-sparing therapy for recalcitrant dermatomyositis","volume":"142","author":"Edge","year":"2006","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.autrev.2011.06.007_bb0295","first-page":"1542","article-title":"Mycophenolate mofetil in the treatment of severe skin manifestations of dermatomyositis: a series of 4 cases","volume":"27","author":"Gelber","year":"2000","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2011.06.007_bb0300","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1093\/rheumatology\/kel336","article-title":"Mycophenolate mofetil treatment in resistant myositis","volume":"46","author":"Pisoni","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2011.06.007_bb0305","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.autrev.2009.04.003","article-title":"Intravenous immunoglobulin as add on treatment with mycophenolate mofetil in severe myositis","volume":"9","author":"Danieli","year":"2009","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2011.06.007_bb0310","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1378\/chest.130.1.30","article-title":"Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease","volume":"130","author":"Swigris","year":"2006","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.autrev.2011.06.007_bb0315","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.semarthrit.2010.08.003","article-title":"Infectious complications in polymyositis and dermatomyositis. A series of 279 patients","volume":"41","author":"Marie","year":"2011","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2011.06.007_bb0320","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1212\/01.wnl.0000208416.32471.c0","article-title":"Mycophenolate mofetil in dermatomyositis: is it safe?","volume":"66","author":"Rowin","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2011.06.007_bb0325","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1016\/S0140-6736(99)01927-3","article-title":"Tacrolimus in refractory polymyositis with interstitial lung disease","volume":"353","author":"Oddis","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2011.06.007_bb0330","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1007\/s10067-004-0865-z","article-title":"Efficacy of tacrolimus in treatment of polymyositis associated with myasthenia gravis","volume":"23","author":"Shimojima","year":"2004","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2011.06.007_bb0335","first-page":"270","article-title":"Plasma exchange in polymyositis and dermatomyositis: a multicenter study of 57 cases","volume":"13","author":"Cherin","year":"1995","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2011.06.007_bb0340","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1056\/NEJM199205213262102","article-title":"Controlled trial of plasma exchange and leukapheresis in polymyositis and dermatomyositis","volume":"326","author":"Miller","year":"1992","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.autrev.2011.06.007_bb0345","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.autrev.2011.04.028","article-title":"Therapeutic plasma exchange for the management of refractory systemic autoimmune diseases: Report of 31 cases and review of the literature","volume":"10","author":"Pons-Estel","year":"2011","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2011.06.007_bb0350","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1093\/rheumatology\/keh539","article-title":"Advanced refractory polymyositis responding to infliximab","volume":"44","author":"Anandacoomarasamy","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2011.06.007_bb0355","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1136\/ard.2005.048744","article-title":"Possible role for tumour necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a retrospective study of eight patients","volume":"65","author":"Efthimiou","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2011.06.007_bb0360","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1159\/000070852","article-title":"Successful treatment of dermatomyositis and polymyositis with anti-tumor-necrosis-factor-alpha: preliminary observations","volume":"50","author":"Hengstman","year":"2003","journal-title":"Eur Neurol"},{"key":"10.1016\/j.autrev.2011.06.007_bb0365","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1093\/rheumatology\/keh079","article-title":"Refractory polymyositis responding to infliximab: extended follow-up","volume":"43","author":"Labioche","year":"2004","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2011.06.007_bb0370","first-page":"1802","article-title":"Use of etanercept in the treatment of dermatomyositis: a case series","volume":"33","author":"Iannone","year":"2006","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2011.06.007_bb0375","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1093\/rheumatology\/keh062","article-title":"Treatment of myositis with etanercept (Enbrel), a recombinant human soluble fusion protein of TNF-alpha type II receptor and IgG1","volume":"43","author":"Sprott","year":"2004","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2011.06.007_bb0380","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1136\/ard.2007.077974","article-title":"A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies","volume":"67","author":"Dastmalchi","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2011.06.007_bb0385","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/art.20849","article-title":"Rituximab in the treatment of dermatomyositis: an open-label pilot study","volume":"52","author":"Levine","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2011.06.007_bb0390","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1001\/archdermatol.2010.142","article-title":"Tumor necrosis factor inhibitor-associated dermatomyositis","volume":"146","author":"Klein","year":"2010","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.autrev.2011.06.007_bb0395","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1136\/ard.2005.045898","article-title":"Rituximab in the treatment of antisynthetase syndrome","volume":"65","author":"Brulhart","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2011.06.007_bb0400","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1097\/01.rhu.0000182155.08982.60","article-title":"Rituximab in the treatment of refractory dermatomyositis","volume":"11","author":"Chiappetta","year":"2005","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.autrev.2011.06.007_bb0405","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1001\/archderm.143.6.763","article-title":"A pilot trial of rituximab in the treatment of patients with dermatomyositis","volume":"143","author":"Chung","year":"2007","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.autrev.2011.06.007_bb0410","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jaad.2006.05.068","article-title":"Rituximab for the treatment of the skin manifestations of dermatomyositis: a report of 3 cases","volume":"56","author":"Dinh","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.autrev.2011.06.007_bb0415","first-page":"1369","article-title":"Efficacy of rituximab in refractory polymyositis","volume":"32","author":"Lambotte","year":"2005","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2011.06.007_bb0420","first-page":"1864","article-title":"Rituximab for refractory polymyositis: an open-label prospective study","volume":"34","author":"Mok","year":"2007","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2011.06.007_bb0425","first-page":"1021","article-title":"Rituximab as therapy for refractory polymyositis and dermatomyositis","volume":"33","author":"Noss","year":"2006","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2011.06.007_bb0430","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1136\/ard.2004.029694","article-title":"Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases","volume":"64","author":"Gottenberg","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2011.06.007_bb0435","first-page":"1230","article-title":"Longlasting remissions after treatment with rituximab for autoimmune myositis","volume":"35","author":"Feist","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2011.06.007_bb0440","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1093\/rheumatology\/kep157","article-title":"Rituximab treatment of the anti-synthetase syndrome: a retrospective case series","volume":"48","author":"Sem","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2011.06.007_bb0445","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1016\/j.ejim.2011.01.001","article-title":"Progressive multifocal leukoencephalopathy in refractory polymyositis treated with rituximab","volume":"22","author":"Marie","year":"2011","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.autrev.2011.06.007_bb0450","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1080\/030097400447679","article-title":"The safety of a resistive home exercise program in patients with recent onset active polymyositis or dermatomyositis","volume":"29","author":"Alexanderson","year":"2000","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.autrev.2011.06.007_bb0455","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1093\/rheumatology\/37.2.196","article-title":"Improvement of physical fitness and muscle strength in polymyositis\/dermatomyositis patients by a training programme","volume":"37","author":"Wiesinger","year":"1998","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.autrev.2011.06.007_bb0460","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1093\/rheumatology\/37.12.1338","article-title":"Benefit of 6months long-term physical training in polymyositis\/dermatomyositis patients","volume":"37","author":"Wiesinger","year":"1998","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.autrev.2011.06.007_bb0465","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1002\/art.21185","article-title":"Safety and efficacy of submaximal eccentric strength training for a subject with polymyositis","volume":"53","author":"Harris-Love","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2011.06.007_bb0470","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.autrev.2008.11.008","article-title":"The possible role of physical exercise on the treatment of idiopathic inflammatory myopathies","volume":"8","author":"de Salles Painelli","year":"2009","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2011.06.007_bb0475","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.autrev.2009.02.026","article-title":"Idiopathic inflammatory myopathies and the classical NF-kappaB complex: current insights and implications for therapy","volume":"8","author":"Creus","year":"2009","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2011.06.007_bb0480","unstructured":"Dalakas MC. Pathogenesis and therapies of immune-mediated myopathies. Autoimmun Rev in press, doi:10\/1016\/j.autrev.2011.05.013."},{"key":"10.1016\/j.autrev.2011.06.007_bb0485","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.autrev.2010.02.011","article-title":"Vitamin D and autoimmune rheumatologic disorders","volume":"9","author":"Pelajo","year":"2010","journal-title":"Autoimmun Rev"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997211001492?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997211001492?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T19:21:21Z","timestamp":1543692081000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997211001492"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11]]},"references-count":97,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,11]]}},"alternative-id":["S1568997211001492"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2011.06.007","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2011,11]]}}}